Physician profile
Todd Rhoades
NPI 1487676706
$12,235.04
in general payments reported to CMS, 2019-2025
46 companies · $2,786 in 2025
The $2,786 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,059 · 2020: $603 · 2021: $83.04 · 2022: $1,366 · 2023: $2,188 · 2024: $2,149 · 2025: $2,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,080 · Education: $43.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,080.32 |
| Education | $43.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,702.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,153.39 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,135.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,125.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $952.05 | 2022-2025 | |
| Amgen INC. | $766.90 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $693.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.35 | 2019-2025 | Jardiance, Spiriva Respimat |
| Astellas Pharma US INC | $412.89 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $329.75 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $308.64 | 2022-2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $298.47 | 2019-2020 | |
| Axsome Therapeutics, INC. | $238.78 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $231.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $228.68 | 2019-2025 | Vaxneuvance, Gardasil 9, Rotateq |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Rhoades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.